Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 5/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | JAK3 | P52333 | 1/20 | 0.45 |
| ▸ | ITK | Q08881 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | ULK2 | Q8IYT8 | 3/20 | 0.44 |
| ▸ | FLT3 | P36888 | 2/20 | 0.44 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.44 |
| ▸ | MERTK | Q12866 | 2/20 | 0.44 |
| ▸ | GAS6 | Q14393 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 9/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19654497 | 0.86 | AURKA (0.59) | ULK1EGFRJAK3ITKAURKA | |
| SCHEMBL19654378 | 0.84 | TYRO3 (0.59) | ULK1EGFRJAK3ITKAURKA | |
| SCHEMBL29695649 | 0.82 | EGFR (0.61) | ULK1EGFRJAK3ITKAURKA | |
| SCHEMBL17544434 | 0.81 | ULK1 (1.00) | ULK1ULK2 | |
| SCHEMBL19654496 | 0.80 | ULK1 (0.67) | ULK1EGFRJAK3ITKAURKA | |
| SCHEMBL19654389 | 0.80 | ULK1 (0.47) | ULK1EGFRJAK3ITKAURKA | |
| SCHEMBL19654499 | 0.79 | ULK1 (0.70) | ULK1EGFRULK2FLT3SYK | |
| SCHEMBL19654337 | 0.78 | ULK1 (0.51) | ULK1EGFRJAK3ITKFLT3 | |
| SCHEMBL29695680 | 0.77 | EGFR (0.65) | EGFRJAK3ITKAURKATYRO3 | |
| SCHEMBL29695669 | 0.77 | EGFR (0.65) | EGFRJAK3ITKAURKATYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342088-A1 | NOVEL ULK1 INHIBITORS AND METHODS USING SAME | ULK1, ULK2, ULK3 | ULK1 1/4885EGFR 3147/4885JAK3 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.